CES 2022 | Abbott's next-gen biowearables are rated to turn your smartphone into an enhanced personal bio-tracking system
Abbott is a company mainly associated with the areas of diagnostics, cardiac implants such as stents and medicines from ibuprofen to ACE inhibitors. However, it has also recently found success in the European market with the FreeStyle Libre series of "biowearables", suitable for use by consumers with conditions such as diabetes. They help people such as the comedian Sherri Shepherd and the world-record marathon runner Eliud Kipchoge manage and monitor their glucose levels.
Now, Abbott has "headlined" CES for the first time in 2022 to unveil the expansion of this product line, which require that they pierce the skin in order to be kept on one arm. This new Lingo series will do much the same in order to track glucose, lactate or ketone levels.
Abbott asserts that a Lingo biowearable will gather and analyze data with high sensitivity and efficacy, and send the results to the user's smartphone, as a smartwatch or fitness tracker would. This, as the OEM's chairman and CEO. Robert B. Ford, will afford customers "a window into [their] body".
On the other hand, despite Abbott's reputation, the in-development Lingo series is not intended to match up to clinical or formal diagnostic standards. In any case, it may encounter competitors such as other, potentially non-invasive, glucose monitors on its launch.